stanozolol has been researched along with Scleroderma, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayres, ML; Browse, NL; Jarrett, PE | 1 |
| Holland, CD; Illingworth, K; Jayson, MI; Keegan, A; Taylor, L | 1 |
1 trial(s) available for stanozolol and Scleroderma, Systemic
| Article | Year |
|---|---|
A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis.
Topics: Adult; Double-Blind Method; Female; Fibrinolysis; Humans; Male; Raynaud Disease; Regional Blood Flow; Scleroderma, Systemic; Stanozolol | 1991 |
1 other study(ies) available for stanozolol and Scleroderma, Systemic
| Article | Year |
|---|---|
Blood viscosity, Raynaud's phenomenon and the effect of fibrinolytic enhancement.
Topics: Adult; Blood Viscosity; Female; Fibrinogen; Fibrinolysis; Hand; Hematocrit; Humans; Male; Middle Aged; Raynaud Disease; Regional Blood Flow; Scleroderma, Systemic; Stanozolol | 1981 |